ATC code L01

From WikiProjectMed
Jump to navigation Jump to search
ATC codes
L Antineoplastic and immunomodulating agents
L01 Antineoplastic agents
L02 Endocrine therapy
L03 Immunostimulants
L04 Immunosuppressants

ATC code L01 Antineoplastic agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2] Subgroup L01 is part of the anatomical group L Antineoplastic and immunomodulating agents.[3]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL01.[4] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.

National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

L01A Alkylating agents

L01AA Nitrogen mustard analogues

L01AA01 Cyclophosphamide
L01AA02 Chlorambucil
L01AA03 Melphalan
L01AA05 Chlormethine
L01AA06 Ifosfamide
L01AA07 Trofosfamide
L01AA08 Prednimustine
L01AA09 Bendamustine

L01AB Alkyl sulfonates

L01AB01 Busulfan
L01AB02 Treosulfan
L01AB03 Mannosulfan

L01AC Ethylene imines

L01AC01 Thiotepa
L01AC02 Triaziquone
L01AC03 Carboquone

L01AD Nitrosoureas

L01AD01 Carmustine
L01AD02 Lomustine
L01AD03 Semustine
L01AD04 Streptozocin
L01AD05 Fotemustine
L01AD06 Nimustine
L01AD07 Ranimustine
L01AD08 Uramustine

L01AG Epoxides

L01AG01 Etoglucid

L01AX Other alkylating agents

L01AX01 Mitobronitol
L01AX02 Pipobroman
L01AX03 Temozolomide
L01AX04 Dacarbazine

L01B Antimetabolites

L01BA Folic acid analogues

L01BA01 Methotrexate
L01BA03 Raltitrexed
L01BA04 Pemetrexed
L01BA05 Pralatrexate

L01BB Purine analogues

L01BB02 Mercaptopurine
L01BB03 Tioguanine
L01BB04 Cladribine
L01BB05 Fludarabine
L01BB06 Clofarabine
L01BB07 Nelarabine
QL01BB90 Rabacfosadine

L01BC Pyrimidine analogues

L01BC01 Cytarabine
L01BC02 Fluorouracil
L01BC03 Tegafur
L01BC04 Carmofur
L01BC05 Gemcitabine
L01BC06 Capecitabine
L01BC07 Azacitidine
L01BC08 Decitabine
L01BC09 Floxuridine
L01BC52 Fluorouracil, combinations
L01BC53 Tegafur, combinations
L01BC59 Trifluridine, combinations

L01C Plant alkaloids and other natural products

L01CA Vinca alkaloids and analogues

L01CA01 Vinblastine
L01CA02 Vincristine
L01CA03 Vindesine
L01CA04 Vinorelbine
L01CA05 Vinflunine
L01CA06 Vintafolide

L01CB Podophyllotoxin derivatives

L01CB01 Etoposide
L01CB02 Teniposide

L01CC Colchicine derivatives

L01CC01 Demecolcine

L01CD Taxanes

L01CD01 Paclitaxel
L01CD02 Docetaxel
L01CD03 Paclitaxel poliglumex
L01CD04 Cabazitaxel

L01CE Topoisomerase 1 (TOP1) inhibitors

L01CE01 Topotecan
L01CE02 Irinotecan
L01CE03 Etirinotecan pegol
L01CE04 Belotecan

L01CX Other plant alkaloids and natural products

L01CX01 Trabectedin

L01D Cytotoxic antibiotics and related substances

L01DA Actinomycines

L01DA01 Dactinomycin

L01DB Anthracyclines and related substances

L01DB01 Doxorubicin
L01DB02 Daunorubicin
L01DB03 Epirubicin
L01DB04 Aclarubicin
L01DB05 Zorubicin
L01DB06 Idarubicin
L01DB07 Mitoxantrone
L01DB08 Pirarubicin
L01DB09 Valrubicin
L01DB10 Amrubicin
L01DB11 Pixantrone

L01DC Other cytotoxic antibiotics

L01DC01 Bleomycin
L01DC02 Plicamycin
L01DC03 Mitomycin
L01DC04 Ixabepilone

L01E Protein kinase inhibitors

L01EA BCR-ABL tyrosine kinase inhibitors

L01EA01 Imatinib
L01EA02 Dasatinib
L01EA03 Nilotinib
L01EA04 Bosutinib
L01EA05 Ponatinib

L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

L01EB01 Gefitinib
L01EB02 Erlotinib
L01EB03 Afatinib
L01EB04 Osimertinib
L01EB05 Rociletinib
L01EB06 Olmutinib
L01EB07 Dacomitinib
L01EB08 Icotinib

L01EC B-Raf serine-threonine kinase (BRAF) inhibitors

L01EC01 Vemurafenib
L01EC02 Dabrafenib
L01EC03 Encorafenib

L01ED Anaplastic lymphoma kinase (ALK) inhibitors

L01ED01 Crizotinib
L01ED02 Ceritinib
L01ED03 Alectinib
L01ED04 Brigatinib
L01ED05 Lorlatinib

L01EE Mitogen-activated protein kinase (MEK) inhibitors

L01EE01 Trametinib
L01EE02 Cobimetinib
L01EE03 Binimetinib
L01EE04 Selumetinib

L01EF Cyclin-dependent kinase (CDK) inhibitors

L01EF01 Palbociclib
L01EF02 Ribociclib
L01EF03 Abemaciclib

L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors

L01EG01 Temsirolimus
L01EG02 Everolimus
L01EG03 Ridaforolimus

L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors

L01EH01 Lapatinib
L01EH02 Neratinib
L01EH03 Tucatinib

L01EJ Janus-associated kinase (JAK) inhibitors

L01EJ01 Ruxolitinib
L01EJ02 Fedratinib

L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors

L01EK01 Axitinib
L01EK02 Cediranib
L01EK03 Tivozanib

L01EL Bruton's tyrosine kinase (BTK) inhibitors

L01EL01 Ibrutinib
L01EL02 Acalabrutinib
L01EL03 Zanubrutinib

L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors

L01EM01 Idelalisib
L01EM02 Copanlisib
L01EM03 Alpelisib
L01EM04 Duvelisib

L01EX Other protein kinase inhibitors

L01EX01 Sunitinib
L01EX02 Sorafenib
L01EX03 Pazopanib
L01EX04 Vandetanib
L01EX05 Regorafenib
L01EX06 Masitinib
L01EX07 Cabozantinib
L01EX08 Lenvatinib
L01EX09 Nintedanib
L01EX10 Midostaurin
L01EX11 Quizartinib
L01EX12 Larotrectinib
L01EX13 Gilteritinib
L01EX14 Entrectinib
L01EX15 Pexidartinib
L01EX16 Erdafitinib
L01EX17 Capmatinib
L01EX18 Avapritinib
L01EX19 Ripretinib
L01EX20 Pemigatinib
L01EX21 Tepotinib
QL01EX90 Toceranib

L01X Other antineoplastic agents

L01XA Platinum compounds

L01XA01 Cisplatin
L01XA02 Carboplatin
L01XA03 Oxaliplatin
L01XA04 Satraplatin
L01XA05 Polyplatillen

L01XB Methylhydrazines

L01XB01 Procarbazine

L01XC Monoclonal antibodies

L01XC01 Edrecolomab
L01XC02 Rituximab
L01XC03 Trastuzumab
L01XC05 Gemtuzumab ozogamicin
L01XC06 Cetuximab
L01XC07 Bevacizumab
L01XC08 Panitumumab
L01XC09 Catumaxomab
L01XC10 Ofatumumab
L01XC11 Ipilimumab
L01XC12 Brentuximab vedotin
L01XC13 Pertuzumab
L01XC14 Trastuzumab emtansine
L01XC15 Obinutuzumab
L01XC16 Dinutuximab beta
L01XC17 Nivolumab
L01XC18 Pembrolizumab
L01XC19 Blinatumomab
L01XC21 Ramucirumab
L01XC22 Necitumumab
L01XC23 Elotuzumab
L01XC24 Daratumumab
L01XC25 Mogamulizumab
L01XC26 Inotuzumab ozogamicin
L01XC27 Olaratumab
L01XC28 Durvalumab
L01XC29 Bermekimab
L01XC31 Avelumab
L01XC32 Atezolizumab
L01XC33 Cemiplimab
L01XC34 Moxetumomab pasudotox
L01XC35 Tafasitamab
L01XC36 Enfortumab vedotin
L01XC37 Polatuzumab vedotin
L01XC38 Isatuximab
L01XC39 Belantamab mafodotin
L01XC40 Dostarlimab
L01XC41 Trastuzumab deruxtecan

L01XD Sensitizers used in photodynamic/radiation therapy

L01XD01 Porfimer sodium
L01XD03 Methyl aminolevulinate
L01XD04 Aminolevulinic acid
L01XD05 Temoporfin
L01XD06 Efaproxiral
L01XD07 Padeliporfin

L01XF Retinoids for cancer treatment

L01XF01 Tretinoin
L01XF02 Alitretinoin
L01XF03 Bexarotene

L01XG Proteasome inhibitors

L01XG01 Bortezomib
L01XG02 Carfilzomib
L01XG03 Ixazomib

L01XH Histone deacetylase (HDAC) inhibitors

L01XH01 Vorinostat
L01XH02 Romidepsin
L01XH03 Panobinostat
L01XH04 Belinostat
L01XH05 Entinostat

L01XJ Hedgehog pathway inhibitors

L01XJ01 Vismodegib
L01XJ02 Sonidegib
L01XJ03 Glasdegib

L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors

L01XK01 Olaparib
L01XK02 Niraparib
L01XK03 Rucaparib
L01XK04 Talazoparib
L01XK05 Veliparib

L01XX Other antineoplastic agents

L01XX01 Amsacrine
L01XX02 Asparaginase
L01XX03 Altretamine
L01XX05 Hydroxycarbamide
L01XX07 Lonidamine
L01XX08 Pentostatin
L01XX10 Masoprocol
L01XX11 Estramustine
L01XX16 Mitoguazone
L01XX18 Tiazofurine
L01XX23 Mitotane
L01XX24 Pegaspargase
L01XX27 Arsenic trioxide
L01XX29 Denileukin diftitox
L01XX33 Celecoxib
L01XX35 Anagrelide
L01XX36 Oblimersen
L01XX37 Sitimagene ceradenovec
L01XX40 Omacetaxine mepesuccinate
L01XX41 Eribulin
L01XX44 Aflibercept
L01XX46 Olaparib
L01XX51 Talimogene laherparepvec
L01XX52 Venetoclax
L01XX53 Vosaroxin
L01XX57 Plitidepsin
L01XX58 Epacadostat
L01XX59 Enasidenib
L01XX62 Ivosidenib
L01XX66 Selinexor
L01XX67 Tagraxofusp
L01XX69 Lurbinectedin
L01XX70 Axicabtagene ciloleucel
L01XX71 Tisagenlecleucel
QL01XX91 Tigilanol tiglate

L01XY Combinations of antineoplastic agents

L01XY01 Cytarabine and daunorubicin
L01XY02 Pertuzumab and trastuzumab


  1. ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 2020-02-01.
  2. ^ "ATC-Klassifikation mit definierten Tagesdosen DDD" (in German). German Institute for Medical Documentation and Information. Retrieved 2020-02-01.
  3. ^ "ATC/DDD Index 2021: code L01". WHO Collaborating Centre for Drug Statistics Methodology.
  4. ^ "ATCvet Index 2021: code QL01". WHO Collaborating Centre for Drug Statistics Methodology.